Items where authors include "Ottensmeier, C."
Up a levelArticle
Wu, Y. orcid.org/0000-0003-4080-3935, Biswas, D. orcid.org/0000-0001-9141-5188, Usaite, I. et al. (302 more authors) (2022) A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer. Nature Cancer, 3. pp. 696-709. ISSN 2662-1347
Fennell, D.A., Griffiths, G., Ottensmeier, C. et al. (4 more authors) (2022) CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. The Lancet Oncology, 23 (1). e14-e15. ISSN 1470-2045
Fennell, D.A., Ewings, S., Ottensmeier, C. et al. (36 more authors) (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology, 22 (11). pp. 1530-1540. ISSN 1470-2045
Coen, O., Corrie, P., Marshall, H. et al. (17 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21 (1). 761. ISSN 1471-2407
Hardy-Werbin, M., Rocha, P., Arpi, O. et al. (13 more authors) (2019) Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. OncoImmunology, 8 (6). e1593810. ISSN 2162-4011
Fennell, D.A., Kirkpatrick, E., Cozens, K. et al. (13 more authors) (2018) CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. TRIALS, 19. 233. ISSN 1745-6215
Arce Vargas, F., Furness, A.J.S., Litchfield, K. et al. (249 more authors) (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33 (4). 649-663.e4. ISSN 1535-6108
Arriola, E., Wheater, M., Galea, I. et al. (13 more authors) (2016) Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer. Journal of Thoracic Oncology, 11 (9). pp. 1511-1521. ISSN 1556-0864
Proceedings Paper
Hanna, G., Griffiths, G., Kirkpatrick, E.V. et al. (11 more authors) (2018) CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin. Elsevier , S84-S84.